New AAP guidance emphasizes longitudinal assessment and collaborative partnerships to foster healthy mental and emotional development in children.

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.

Most people that are admitted to the hospital for psychiatric needs are eventually readmitted or engage with hospital-based psychiatry again.

Among Medicare beneficiaries there was a decline in primary care visits, and limited telemedicine use between 2017 and 2023.

Based on data from 2024, an estimated 8 million people in the US have used psilocybin for various purposes in the last year.

The FDA approved expanded use of Auvelity, an extended release major depressive disorder drug, for use in the treatment of Alzheimer disease.

The APA proposed new DSM revisions to incorporate socioeconomic, cultural, and environmental determinants into diagnostic ...

LB-102 vs placebo significantly improved PANSS total scores in adults with acute exacerbation of schizophrenia.

What social risk factors affecting your patients may affect their risk of major depressive disorder more than they realize?

The FDA has updated the label for Caplyta to include phase 3 data showing a significant reduction in schizophrenia relapse risk.

Sustained methylphenidate treatment was not linked to nonaffective psychosis in children and adolescents with ADHD.

The FDA moved approved marijuana products to schedule III to expand therapy access and state medical programs while ...